SG159551A1 - Gip analog and hybrid polypeptides with selectable properties - Google Patents

Gip analog and hybrid polypeptides with selectable properties

Info

Publication number
SG159551A1
SG159551A1 SG201000999-1A SG2010009991A SG159551A1 SG 159551 A1 SG159551 A1 SG 159551A1 SG 2010009991 A SG2010009991 A SG 2010009991A SG 159551 A1 SG159551 A1 SG 159551A1
Authority
SG
Singapore
Prior art keywords
insulin
hybrid polypeptides
disorders
selectable properties
gip analog
Prior art date
Application number
SG201000999-1A
Other languages
English (en)
Inventor
Odile Esther Levy
Michael R Hanley
Carolyn M Jodka
Diana Y Lewis
Christopher J Soares
Soumitra S Ghosh
Lawrence J Daesouza
David G Parkes
Christine M Mack
Ved Srivastava
Samuel Janssen
Alain D Baron
Andrew A Young
Richard A Pittner
Mary Erickson
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of SG159551A1 publication Critical patent/SG159551A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
SG201000999-1A 2005-02-11 2006-02-10 Gip analog and hybrid polypeptides with selectable properties SG159551A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US65164705P 2005-02-11 2005-02-11
US65266205P 2005-02-11 2005-02-11
US65343305P 2005-02-15 2005-02-15
US70736905P 2005-08-11 2005-08-11
US70724405P 2005-08-11 2005-08-11
US70931605P 2005-08-17 2005-08-17
US70932005P 2005-08-17 2005-08-17

Publications (1)

Publication Number Publication Date
SG159551A1 true SG159551A1 (en) 2010-03-30

Family

ID=36588963

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201000999-1A SG159551A1 (en) 2005-02-11 2006-02-10 Gip analog and hybrid polypeptides with selectable properties

Country Status (14)

Country Link
US (2) US8404637B2 (fr)
EP (3) EP2392595A1 (fr)
JP (1) JP2008530130A (fr)
KR (1) KR20070115947A (fr)
AU (1) AU2006213607A1 (fr)
BR (1) BRPI0606992A2 (fr)
CA (1) CA2597649A1 (fr)
EA (1) EA011653B1 (fr)
IL (1) IL185563A0 (fr)
MX (1) MX2007009760A (fr)
NO (1) NO20074545L (fr)
NZ (1) NZ561361A (fr)
SG (1) SG159551A1 (fr)
WO (1) WO2006086769A2 (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6048625A (ja) * 1983-08-29 1985-03-16 Anritsu Corp ２重スーパヘテロダイン受信機
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2589800A1 (fr) * 2004-12-02 2006-06-08 Domantis Limited Anticorps a domaine bispecifiques ciblant l'albumine serique et le glp 1ou le pyy
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8404637B2 (en) 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP1912666A2 (fr) * 2005-07-22 2008-04-23 Amylin Pharmaceuticals, Inc. Utilisation d'amyline et d'agonistes d'amyline comme agents cardioprotecteurs ou myoprotecteurs
EP2330124B1 (fr) * 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Polypeptides hybrides ayant des propriétés sélectionnables
CA2628241C (fr) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
CA2638800A1 (fr) * 2006-02-22 2007-09-07 Merck & Co., Inc. Derives d'oxyntomoduline
JP2009532422A (ja) * 2006-04-03 2009-09-10 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１ペプチドアゴニスト
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US8497240B2 (en) * 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008021560A2 (fr) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Analogue du gip et polypeptides hybrides possédant des propriétés sélectives
AU2008205229B2 (en) * 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
KR101581476B1 (ko) * 2007-07-20 2015-12-30 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 나트륨이뇨성 폴리펩티드
US20100184698A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Use of a deslorelin and mastoparan as a therapeutic agent
RU2010114013A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение нейротрофического фактора для холинергических нейронов сетчатки (nfrcn) и хорионического гонадотропина бета (109-145) в качестве терапевтических средств
WO2009033773A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
GB0721131D0 (en) * 2007-10-27 2007-12-05 Univ Belfast "Peptide and users thereof"
CA2707861A1 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Antagonistes du glucagon
CA2702289A1 (fr) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Composes presentant une activite d'antagoniste de glucagon et d'agoniste du glp-1
EP2224945B1 (fr) * 2007-11-23 2012-05-16 Michael Rothkopf Procédés d'amplification de la résolution d'un diabète
WO2009099763A1 (fr) * 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Promédicaments peptidiques à base d’esters
CA2726861C (fr) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
EA023069B1 (ru) * 2008-04-09 2016-04-29 Корнелл Юниверсити Изолированные рекомбинантные кишечные симбиотические бактерии и их применение
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
EP2952202B1 (fr) * 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
EA020018B1 (ru) * 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Процессированные аналоги глюкозозависимого инсулинотропного полипептида
AU2009280017B2 (en) 2008-08-07 2013-01-10 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
WO2010016938A2 (fr) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues de polypeptide insulinotrope glucose-dépendant
MX339137B (es) * 2008-08-07 2016-05-13 Ipsen Pharma Sas Analogos de polipeptidos insulinotropicos dependientes de glucosa (gip) modificados en n terminal.
AR074811A1 (es) 2008-12-19 2011-02-16 Univ Indiana Res & Tech Corp Profarmaco de peptido de la superfamilia de glucagon basados en amida
JP5576694B2 (ja) * 2009-04-10 2014-08-20 花王株式会社 Ｇｉｐ上昇抑制剤
KR20120087875A (ko) 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Ｇｉｐ 수용체-활성 글루카곤 화합물
WO2011006644A2 (fr) * 2009-07-15 2011-01-20 Lonza Ltd Procédé de production de l’exénatide et d’un analogue de l’exénatide
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
KR20120116942A (ko) * 2009-11-23 2012-10-23 아밀린 파마슈티칼스, 인크. 폴리펩티드 접합체
EP2512503A4 (fr) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Co-agonistes du récepteur du glucagon/glp-i
MX2012008603A (es) * 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
JP2013526535A (ja) * 2010-05-11 2013-06-24 エヌピーエス ファーマシューティカルズ インコーポレイテッド 腎機能障害または肝機能障害の治療または予防のための方法
CA2797089A1 (fr) * 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille du glucagon manifestant une activite de recepteur couple a une proteine g
CA2797095A1 (fr) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille des glucagons presentant une activite de recepteur nucleaire d'hormone
WO2011163012A2 (fr) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Promédicaments peptidiques à base d'amides de la superfamille du glucagon
BR112013008957A2 (pt) 2010-10-15 2019-09-24 Univ Cornell composições e métodos para tratamento de doenças endócrinas, gastrointestinais ou autoimunes
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
BR112013015389A2 (pt) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012115772A2 (fr) 2011-02-25 2012-08-30 Medtronic, Inc. Thérapie pour néphropathie et/ou insuffisance cardiaque
BR112013024784A2 (pt) 2011-04-07 2018-09-25 Univ Leland Stanford Junior análogos de peptídeos de ação prolongada
BR112013030067A2 (pt) * 2011-05-25 2016-11-29 Amylin Pharmaceuticals Llc "conjugado polipeptídico, composição farmacêutica compreendendo o referido conjugado e uso do mesmo"
CA2838503C (fr) * 2011-06-10 2020-02-18 Hanmi Science Co., Ltd. Derives inedits d'oxyntomoduline et composition pharmaceutique destinee au traitement de l'obesite en contenant
EP2718317B1 (fr) * 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Analogues de polypeptides insulinotropes dépendants du glucose, compositions pharmaceutiques et son utilisation
PH12018501119A1 (en) * 2011-06-17 2019-02-04 Hanmi Science Co Ltd A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
CN103857408B (zh) 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
RU2514093C2 (ru) * 2011-08-09 2014-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО СибГМУ Минздравсоцразвития России) Средство для инъекционной терапии гастроэзофагеальной рефлюксной болезни
EP2750697A4 (fr) 2011-09-02 2015-03-25 Medtronic Inc Compositions de peptides natriurétiques chimériques et procédés de préparation
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
WO2013103896A1 (fr) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Traitement de maladies cardiovasculaires ou rénales
KR101855242B1 (ko) * 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
EP2864351B1 (fr) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Analogues du glucagon présentant une activité sur le récepteur du gip
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EA031852B1 (ru) 2012-11-06 2019-03-29 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
ES2900744T3 (es) 2013-05-28 2022-03-18 Takeda Pharmaceuticals Co Compuesto de péptidos
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
WO2015086730A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 non acylés
WO2015086729A1 (fr) 2013-12-13 2015-06-18 Sanofi Agonistes mixtes des récepteurs glp-1/gip
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3189072B1 (fr) 2014-09-05 2018-07-18 University of Copenhagen Peptides analogues du gip
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2016049190A1 (fr) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Conjugués d'insuline-incrétines
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2883345T3 (es) * 2014-10-29 2021-12-07 Zealand Pharma As Compuestos agonistas del GIP y métodos
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
MX2018007859A (es) 2015-12-23 2018-11-09 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
EP3400237A4 (fr) 2016-01-04 2020-03-04 Adepthera LLC Analogues peptidiques
US10893832B2 (en) * 2016-01-13 2021-01-19 Tufts Medical Center, Inc. Predictive instrument to identify patients for use of pharmacological cardiac metabolic support
US11701409B2 (en) 2016-02-09 2023-07-18 Adepthera Llc Dosing and use of long-acting CLR/ramp agonists
WO2017200943A1 (fr) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Polypeptides sélectifs du récepteur du glucagon et méthodes pour les employer
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018045083A1 (fr) 2016-09-02 2018-03-08 Soares Christopher J Utilisation d'antagonistes du récepteur cgrp en neuroprotection et pour le traitement de troubles neurologiques
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
PL3630806T3 (pl) 2017-05-31 2024-05-13 The University Of Copenhagen Analogi peptydów gip o długotrwałym działaniu
CA3067674A1 (fr) * 2017-06-29 2019-01-03 Ureka Sarl Peptide pro-medicament ayant des proprietes pharmaceutiques ameliorees
EP3645031A4 (fr) 2017-06-30 2021-03-31 Adepthera LLC Analogues peptidiques
EP3856339A1 (fr) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Composés peptidiques agonistes du récepteur gip et leurs utilisations
US20220298218A1 (en) * 2018-12-03 2022-09-22 Antag Therapeutics Aps Modified GIP Peptide Analogues
WO2020148317A1 (fr) 2019-01-18 2020-07-23 Ureka Sarl Composés hybrides de peptide-oligourée
AU2020398675A1 (en) * 2019-12-03 2022-05-26 Antag Therapeutics Aps Optimized GIP peptide analogues
AU2021260870A1 (en) * 2020-04-20 2022-12-08 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
CN117881415A (zh) * 2021-06-10 2024-04-12 安泰博医药 肥胖症和肥胖症相关障碍的治疗
CA3226003A1 (fr) * 2021-07-16 2023-01-19 Pep2Tango Therapeutics Inc. Compositions comprenant des peptides multi-agonistes, procedes de fabrication et methodes d'utilisation

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US206903A (en) 1878-08-13 Improvement in cultivators
US3490597A (en) 1966-07-22 1970-01-20 Purolator Products Inc Cover plate for spin-on-filter
EP0024807B1 (fr) 1979-07-28 1983-11-02 Beecham Group Plc Acides benzocycloheptapyrrole alcanoiques, procédés pour leur préparation et compositions pharmaceutiques les contenant
EP0047921A1 (fr) 1980-09-15 1982-03-24 Menzel GmbH. + Co. Procédé et dispositif pour l'aération d'un liquide, particulièrement d'eau usée
US4401593A (en) 1982-02-12 1983-08-30 Armour Pharmaceutical Company Glycine - 8 calcitonin
US4397780A (en) 1982-02-12 1983-08-09 Armour Pharmaceutical Company Leucine22 -calcitonin
CA1187523A (fr) 1982-02-22 1985-05-21 Edgar H. Lais Machine d'exercice a poulie
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4414149A (en) 1983-03-04 1983-11-08 Armour Pharmaceutical Company Glycine8 -D-arginine24 calcitonin
US4497731A (en) 1983-04-04 1985-02-05 Armour Pharmaceutical Company Glycine 8-des-tyrosine 22 calcitonin
US4495097A (en) 1983-04-04 1985-01-22 Armour Pharmaceutical Company Des-serine2 -glycine8 calcitonin
US5188666A (en) 1983-06-30 1993-02-23 Boccardo Victor N Paint removing compositions and methods for the manufacture and use thereof
US4597900A (en) 1983-08-22 1986-07-01 Armour Pharmaceutical Co. Des2 -glycine8 -des22 -calcitonin
US4537716A (en) 1983-12-05 1985-08-27 Armour Pharmaceutical Co. Des-serine2 or des-glycine2 -leucine22 calcitonin
US4604238A (en) 1984-12-10 1986-08-05 Armour Pharmaceutical Company Analogs of calcitonin
US4606856A (en) 1985-03-18 1986-08-19 Seyler Jay K [Des-1-amino, 8-glycine]calcitonin
US4652627A (en) 1985-08-16 1987-03-24 Kempe Tomas G Calcitonin analogs with C-terminal D-amino acid substituents
US4687839A (en) 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
US4697002A (en) 1985-12-23 1987-09-29 Kempe Tomas G Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
AU3342689A (en) 1988-03-24 1989-10-16 Igen Incorporated Luminescent chimeric proteins
DE68929566D1 (de) 1988-05-13 2010-01-28 Amgen Inc Verfahren zur Isolierung und Reinigung von G-CSF
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (fr) 1988-05-31 1997-08-05 John Lewicki Techniques recombinantes pour la production de nouveaux natriuretiques et de peptides vasodilatateurs
CA2006596C (fr) 1988-12-22 2000-09-05 Rika Ishikawa G-csf modifie chimiquement
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
JPH04145099A (ja) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
SK60893A3 (en) 1990-12-13 1993-10-06 Upjohn Co Fusion polypeptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DE69232453T2 (de) 1991-07-08 2002-07-18 Denso Corp Thermischer Durchflussmesser
US5445781A (en) 1991-08-28 1995-08-29 Centro Sviluppo Settori Impiego S.R.L. Process for the injection molding of non-precatalyzed polymerizable resins at high-pressure and flow
US5509305A (en) 1992-02-12 1996-04-23 Daniel Industries, Inc. Closely coupled, dual turbine volumetric flow meter
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6077822A (en) 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0658568A1 (fr) 1993-12-09 1995-06-21 Eli Lilly And Company Peptides insulinotropes de type glucagon, compositions les contenant et méthode de préparation
WO1995019785A1 (fr) 1994-01-24 1995-07-27 Research Triangle Pharmaceuticals Ltd. Traitement du diabete juvenile
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
CA2225454A1 (fr) 1995-06-30 1997-01-23 Thomas Wesley Stephens Procedes pour le traitement du diabete
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US5773416A (en) 1995-10-25 1998-06-30 The Regents Of The University Of California Methods for restoring or enhancing reproductive function in reproductively impaired hosts
DE29522352U1 (de) 1995-12-12 2002-07-18 Busch Dieter & Co Prueftech Lagemeßsonde zum gegenseitigen Ausrichten von Körpern
ATE320479T1 (de) 1996-01-23 2006-04-15 Indevus Pharmaceuticals Inc Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen
US5912007A (en) 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
CA2257240A1 (fr) 1996-06-06 1997-12-11 Smithkline Beecham P.L.C. Fragments de leptine (proteine ob)
US5686511A (en) 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
WO1998001224A1 (fr) 1996-07-04 1998-01-15 Nikolai Ivanovich Kuchersky Broyeur centrifuge
ES2319936T5 (es) 1996-08-08 2013-06-24 Amylin Pharmaceuticals, Inc. Regulación de la motilidad gastrointestinal
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
CN1230966A (zh) 1996-09-20 1999-10-06 赫彻斯特股份公司 勒帕素拮抗剂在用于治疗ii型糖尿病胰岛素耐受性中的用途
WO1998018486A1 (fr) 1996-10-25 1998-05-07 Icogen Corporation Utilisation de la leptine pour stimuler l'hematopoiese
US7091183B1 (en) 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
WO1998030231A1 (fr) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire
AU6656098A (en) 1997-02-25 1998-09-09 Eli Lilly And Company Treatment of infertility with leptin receptor ligands
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
US5998204A (en) 1997-03-14 1999-12-07 The Regents Of The University Of California Fluorescent protein sensors for detection of analytes
DE69840146D1 (de) 1997-03-14 2008-12-04 Univ California Fluoreszenzprotein-sensoren zur erkennung von analyten
JP2002510193A (ja) 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
AU2951797A (en) 1997-06-06 1998-12-21 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
PT1019077E (pt) 1997-08-08 2008-02-21 Amylin Pharmaceuticals Inc Novos compostos agonistas de exendina
BR9814189A (pt) 1997-11-14 2000-10-03 Amylin Pharmaceuticals Inc "compostos agonistas da exendina"
EP1066314B1 (fr) 1997-11-14 2007-12-26 Amylin Pharmaceuticals, Inc. Nouveaux composes agonistes de l'exendine
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
DE69926007T2 (de) 1998-10-07 2005-12-29 Medical College Of Georgia Research Institute, Inc. Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
MXPA01009805A (es) 1999-03-29 2004-07-30 Univ Ulster Peptido.
DE19921537A1 (de) 1999-05-11 2000-11-23 Dieter Hoersch Verfahren zur Induzierung von Zellwachstum durch Verwendung geeigneter Mittel
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6162260A (en) 1999-05-24 2000-12-19 Novo Nordisk Biochem North America, Inc. Single-bath biopreparation and dyeing of textiles
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
US20030036504A1 (en) 2000-01-10 2003-02-20 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
US6734166B1 (en) 2000-02-08 2004-05-11 North Carolina State University Method of reducing aluminum levels in the central nervous system
JP4237375B2 (ja) 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
EP1356295A2 (fr) 2000-04-27 2003-10-29 Bionebraska, Inc. Test de diagnostic de polypeptide inhibiteur gastrique destine a la detection de la sensibilite aux diabetes de type 2, a une intolerance au glucose, ou a une glycemie a jeun
US6602997B2 (en) 2000-04-27 2003-08-05 Shin-Etsu Bio, Inc. Whole cell and cell-debris polysaccharide
AU5675701A (en) 2000-05-16 2001-11-26 Sanwa Kagaku Kenkyusho Co Agents for preventing or ameliorating insulin resistance and/or obesity
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
CA2417100A1 (fr) 2000-08-02 2002-02-07 Theratechnologies Inc. Peptides biologiques modifies presentant une activite renforcee
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6916492B2 (en) 2001-03-30 2005-07-12 Council Of Scientific & Industrial Research Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
US7317000B2 (en) * 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
WO2003059934A2 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Proteines de fusion d'albumine
CA2472882A1 (fr) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Utilisation de pyy et de glp-1, ou d'un antagoniste correspondant, pour la modification du comportement alimentaire
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
ATE550344T1 (de) * 2002-05-24 2012-04-15 Medtronic Inc Verfahren zur spaltung von polypeptiden
WO2003103572A2 (fr) 2002-06-04 2003-12-18 Eli Lilly And Company Analogues modifies du peptide-1 de type glucagon (glp-1)
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
WO2003103697A2 (fr) 2002-06-11 2003-12-18 Cell Therapeutics Scandinavia Ab Utilisation de composes ayant une activite gip dans le traitement de troubles associes a une perte anormale de cellules et/ou dans le traitement de l'obesite
WO2003105763A2 (fr) 2002-06-14 2003-12-24 Amylin Pharmaceuticals, Inc. Prevention et/ou traitement de maladie enterique inflammatoire au moyen de peptides yy ou d'antagonistes de peptides yy
WO2003105760A2 (fr) 2002-06-15 2003-12-24 Enteromed, Inc. Prevention et traitement d'une steatose hepatique non alcoolique (nafld), par antagonisme du recepteur du polypeptide insulinotropique gluco-dependant (gip)
DE60326002D1 (de) 2002-10-22 2009-03-12 Waratah Pharmaceuticals Inc Behandlung von diabetes.
AU2003290563A1 (en) 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
US6831394B2 (en) 2002-12-11 2004-12-14 General Electric Company Backing material for micromachined ultrasonic transducer devices
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
JP2006514035A (ja) 2002-12-17 2006-04-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 心不整脈の予防および治療
WO2004067548A2 (fr) 2003-01-31 2004-08-12 Theratechnologies Inc. Metabolites chimiquement modifies de peptides regulateurs et methodes de production et d'utilisation associees
WO2004078777A2 (fr) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Proteines protegees contre la dipeptidylpeptidase
EP1608317B1 (fr) 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyle peptidase
EP1633384B1 (fr) 2003-05-15 2012-03-14 Trustees Of Tufts College Analogues stables de glp-1
EP1718665B1 (fr) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Polypeptides hybrides presentant des proprietes pouvant etre choisies
ITRM20040105A1 (it) 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US8404637B2 (en) 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
KR20080050576A (ko) 2005-07-29 2008-06-09 앰프로틴 코포레이션 키메릭 치료제
EP2330124B1 (fr) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Polypeptides hybrides ayant des propriétés sélectionnables
WO2008021560A2 (fr) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Analogue du gip et polypeptides hybrides possédant des propriétés sélectives
JP6226510B2 (ja) 2012-01-27 2017-11-08 キヤノン株式会社 画像処理システム、処理方法及びプログラム
ITMI20130325A1 (it) 2013-03-05 2014-09-06 Telecom Italia Spa Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente
US9816387B2 (en) 2014-09-09 2017-11-14 United Technologies Corporation Attachment faces for clamped turbine stator of a gas turbine engine
CA2914090C (fr) 2015-03-31 2023-08-01 Allen-Vanguard Corporation Recepteur de diffusion en continu du domaine temporel et du domaine de frequence
US9714199B2 (en) 2015-09-17 2017-07-25 I P Creations Limited Concealed amalgamated explosive neutralizer and method of manufacture

Also Published As

Publication number Publication date
US20090036364A1 (en) 2009-02-05
CA2597649A1 (fr) 2006-08-17
WO2006086769A3 (fr) 2006-11-02
US20130196913A1 (en) 2013-08-01
US8404637B2 (en) 2013-03-26
WO2006086769A2 (fr) 2006-08-17
EA200701704A1 (ru) 2008-02-28
JP2008530130A (ja) 2008-08-07
EA011653B1 (ru) 2009-04-28
EP2392595A1 (fr) 2011-12-07
NO20074545L (no) 2007-11-09
US9133260B2 (en) 2015-09-15
NZ561361A (en) 2010-02-26
AU2006213607A1 (en) 2006-08-17
IL185563A0 (en) 2008-01-06
KR20070115947A (ko) 2007-12-06
MX2007009760A (es) 2007-11-07
BRPI0606992A2 (pt) 2009-07-28
EP2390264A1 (fr) 2011-11-30
EP1853627A2 (fr) 2007-11-14

Similar Documents

Publication Publication Date Title
SG159551A1 (en) Gip analog and hybrid polypeptides with selectable properties
WO2008021560A3 (fr) Analogue du gip et polypeptides hybrides possédant des propriétés sélectives
WO2005077072A3 (fr) Polypeptides hybrides presentant des proprietes pouvant etre choisies
WO2007022123A3 (fr) Polypeptides hybrides presentant des proprietes selectionnables
EA200800548A1 (ru) Гибридные полипептиды с селектируемыми свойствами
EP2330125A3 (fr) Polypeptides hybrides ayant des propriétés sélectionnables
SI1808168T1 (sl) Kombinacijska terapija za zdravljenje diabetesa in stanj v zvezi z njim ter za zdravljenje stanj, izboljšanih s povečanjem krvnega GLP-1 nivoja
WO2007104789A3 (fr) Dérivés d'amyline
MX2009006709A (es) Tratamiento de enfermedades relacionadas con il-1beta.
WO2007109354A3 (fr) Conjugués inhibiteur de peptidase-peptide et procédés d'utilisation de ceux-ci
JOP20220024A1 (ar) مركبات مساعدة لـ gipr
WO2009042435A8 (fr) Activateurs de glucokinase
WO2008054200A3 (fr) Utilisation de compositions nutritives pour empêcher des troubles
MX2013005095A (es) Composicion farmaceutica, metodos de tratamiento y usos de la misma.
WO2011127304A3 (fr) Méthodes de traitement d'un sujet en surpoids
MY176679A (en) Use of nutritional compositions for preventing disorders
WO2010029089A3 (fr) Polythérapie pour le traitement du diabète et des états pathologiques apparentés
JP2010522185A5 (fr)
WO2012054526A3 (fr) Thérapies basées sur un ligand de récepteur chimiosensoriel
NZ595314A (en) PHARMACEUTICAL COMPOSITIONS comprising (1S)-1,5-anhydro-1-[5-(4-ethoxybenzy1)-2-methoxy-4- methylpheny1]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and metformin.
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
WO2011161427A3 (fr) Glycoprotéines ayant des propriétés de mobilisation des lipides et utilisations thérapeutiques associées
WO2007023154A3 (fr) Utilisation de composes complexes ferriques pour produire un medicament utilise dans le traitement d'etats de deficience ferrique chez des patients atteints de maladie inflammatoire chronique de l'intestin
MXPA06012143A (es) Arilsulfonamidas y usos relacionados con las mismas.
NZ585704A (en) Modulators of cannabinoid receptor CB1 for treating obesity